4.95
-0.12(-2.37%)
Currency In USD
| Previous Close | 5.07 |
| Open | 4.93 |
| Day High | 5.25 |
| Day Low | 4.92 |
| 52-Week High | 20.71 |
| 52-Week Low | 2.39 |
| Volume | 435,365 |
| Average Volume | 1.59M |
| Market Cap | 151.84M |
| PE | -12.69 |
| EPS | -0.39 |
| Moving Average 50 Days | 5.26 |
| Moving Average 200 Days | 4.28 |
| Change | -0.12 |
If you invested $1000 in Sagimet Biosciences Inc. (SGMT) since IPO date, it would be worth $310.34 as of December 22, 2024 at a share price of $4.95. Whereas If you bought $1000 worth of Sagimet Biosciences Inc. (SGMT) shares 6 months ago, it would be worth $1,178.57 as of December 22, 2024 at a share price of $4.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2024 1:00 PM GMT
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
GlobeNewswire Inc.
Nov 18, 2024 1:00 PM GMT
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity FASN inh
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
GlobeNewswire Inc.
Nov 07, 2024 12:30 PM GMT
SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced